Table 1.
Authors | Year | Design | Nr. of Patients (mPDAC) | Study Details | Synchronous/Metachronous | Morbidity, Grade 3+ |
Mortality | Chemotherapy | Median Overall Survival (Months) |
---|---|---|---|---|---|---|---|---|---|
McKenzie [19] | 2010 | R | 4649 | 92 P 4557 NR |
92/0 | NS | P: 0–17.5 NR: 5.8–34.1% |
P: 36% NR: 38.4% |
From primary res: P: 6.3 NR: 4.9 |
Tao [20] | 2017 | R | 28,918 | 467 P 28,451 NR |
NS | NS | NS | P: 53% NR: 45% |
From primary diagnosis: P: 7 NR: 2 |
Oweira [21] | 2017 | R | 13,233 | 160 P 504 M 14,812 NR |
NS | NS | NS | NS | NS |
Wang [22] | 2019 | R | 2694 | 365 P 2329 NR |
NS | NS | NS | PSM 1: P: 69% NR: 66% |
From primary res (PSM 1): P: 11.6 NR: 9 |
Liu [23] | 2020 | R | 11,541 | 133 P 24 PM 6999 NR |
NS | NS | NS | NS | From primary diagnosis: P: 10–14 NR: 4–6 |